Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
- 1 June 2009
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 55 (6) , 1430-1439
- https://doi.org/10.1016/j.eururo.2008.10.021
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)Journal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final resultsJournal of Clinical Oncology, 2007
- Renal Cell Carcinoma GuidelineEuropean Urology, 2007
- The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following ImmunochemotherapyEuropean Urology Supplements, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Patients with Metastatic Renal Cell Carcinoma with Long-Term Disease-Free Survival After Treatment with Sunitinib and Resection of Residual MetastasesClinical Genitourinary Cancer, 2006
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999